Thread by @aditya942000

LAURAS LABS Q1FY21: Marvellous no's
-Operating Leverage comes into play
-Margins aided by Backward Integration👍
-Finance cost ⬇️
-PAT 11x🚀
-Rev. +77%
- Ebitda Marg.- 29.29% vs 15%
-Pat Marg. 17.63% vs 2.74%

ROCE-32.3% ROE-37% (ANNUALIZED)

Co. has successfully derisked its business from mainly an ARV API co. to diff segments.

FDF
-Has been star performer. Reaping rewards of past inv.
-Good predictability of buss. bcoz healthy order book in both Tender & non-tender seg.
-As per mgt they r at full capacity utilization lets see how much more incremental sales it can generate in FDF.

API's
1.ARV API -Acq. of South African subs. could boost this seg. further.They hv huge cap. of (EFV) demand for whch might be low currently(Need to confirm)
2.Onco API still decent but could perform better as co. indicating of new products in pipeline.

3.Other API-will continue to perform as co. has good orderbook for CVS,Anti-diabetic & PPI's

SYNTHESIS(CDMO)
-Total Active projects inc to 47
-Commercial supplies for 4 prod.
-Scaling up with ASPEN

brownfld exp wil hv shorter payback.
Acq assets of unit in Vizag for Back Integ.